CLEVELAND, Ohio (October 20, 2026)—Progestogen, when used in hormone therapy, is recognized for its benefits in protecting the uterus. A new study suggests that its addition limits the increased risk of composite autoimmune disease associated with estrogen-only therapy. Results of the study will be presented at the 2026 Annual Meeting of The Menopause Society in San Diego, October 20-24, 2026.

CLEVELAND, Ohio (October 20, 2026)—It’s not uncommon for women to experience more gastrointestinal (GI) issues, especially bloating and gas, during menopause due to fluctuating hormone levels that slow down digestion and alter gut function. Anxiety is also common. But are the two problems related? A new study sought to answer that question. Results of the study will be presented at the 2026 Annual Meeting of The Menopause Society in San Diego, October 20-24, 2026.

CLEVELAND, Ohio (October 20, 2026)—Volumes of research have been conducted to better understand how women experience menopause and deal with symptoms such as hot flashes, mood swings, sleep difficulty, and low libido. In reality, however, menopause affects the entire family. A new study sought to examine the male partners’ experience of menopause. Results of the study will be presented at the 2026 Annual Meeting of The Menopause Society in San Diego, October 20-24, 2026.

CLEVELAND, Ohio (October 20, 2026)—Testosterone therapy is not routinely recommended for postmenopausal women, in part because long-term safety data remain limited. It is, however, prescribed off label to help women suffering from low libido. A new study links testosterone therapy in postmenopausal women with a higher risk of incident cardiovascular disease. Results of the study will be presented at the 2026 Annual Meeting of The Menopause Society in San Diego, October 20-24, 2026.

CLEVELAND, Ohio (October 20, 2026)—The dramatic success stories of GLP-1 weight loss medications are dominating the airwaves. Midlife women, who commonly experience weight gain resulting from menopause, have been especially drawn to the drugs. A new study suggests that hormone therapy is associated with greater and sustained weight loss with some GLP-1s. Results of the study will be presented at the 2026 Annual Meeting of The Menopause Society in San Diego October 20-24, 2026.

CLEVELAND, Ohio (October 20, 2026)—An estimated 44% to 60% of perimenopausal women report cognitive changes like forgetfulness and trouble concentrating—also known as brain fog. Despite the effect of these symptoms on quality of life and productivity, there is currently no FDA-approved pharmacological intervention. A new review suggests that ADHD medications may help. Study results will be presented at the 2026 Annual Meeting of The Menopause Society in San Diego October 20-24, 2026.

CLEVELAND, Ohio (October 20, 2026)—Bone mineral density significantly decreases during and after menopause due to dropping levels of estrogen. Historically, estrogen therapy has been prescribed to help protect bones, but a new study suggests that the addition of testosterone therapy may improve results compared with using estrogen alone. Results of the study will be presented at the 2026 Annual Meeting of The Menopause Society in San Diego October 20-24, 2026.